莎普爱思品牌怎么样 申请店铺

我要投票 莎普爱思在滴眼液行业中的票数:357 更新时间:2025-06-19
莎普爱思是哪个国家的品牌?「莎普爱思」是 浙江莎普爱思药业股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人陈德康在2000-07-17期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力莎普爱思品牌出海!将品牌入驻外推网,定制莎普爱思品牌推广信息,可以显著提高莎普爱思产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

莎普爱思怎么样

公司自1978年建厂以来,经历了从“国营浙江平湖制药厂”转制成“浙江平湖制药厂(股份合作)”到“浙江平湖莎普爱思制药有限公司”,再到“浙江莎普爱思制药有限公司”,最终于2008年12月15日更名为“浙江莎普爱思药业股份有限公司”,目前注册资金为4900万元人民币。

公司作为一家专业从事药品研发、生产、经营的综合性制药企业,先后被列为“国家高新技术企业”、“浙江省百家最具投资价值企业”、“浙江省千家成长之星企业”、“浙江省级企业技术中心”、“省级高新技术研究开发中心”、“浙江省标准创新型企业”、“嘉兴市重点企业技术创新团队”、“院士专家工作站”等多项荣誉称号。

目前公司拥有大容量注射剂(玻璃瓶、塑料瓶和多层共挤膜袋)、口服溶液剂、滴眼剂、片剂(含头孢菌素类)、硬胶囊剂(含头孢菌素类)、栓剂、颗粒剂(含头孢菌素类)、干混悬剂(含头孢菌素类)、冲洗剂共10个剂型,近百种规格的产品批准文号。抗白内障新药“莎普爱思”滴眼液和抗青光眼新药“达靓”滴眼液被列入“国家火炬计划项目”。“莎普爱思”滴眼液还荣获国家重点科技攻关项目、国家重点新产品、浙江省名牌产品等多个称号,是国内第一个国家二类眼科专科新药。

几十年来,公司凭着优质的产品,良好的信誉,在市场竞争日益激烈的情况下,赢得了市场,产品销往全国各地,取得了良好的经济效益。近年来公司的产品销量与销售额都呈现出逐年增涨的态势,是平湖市重点扶持的股改上市企业。

在竞争激烈的医药市场中,我公司始终坚持科技兴业、加强管理、保证质量,不断推出各种自主研发的新产品。公司秉承“科技创新、求是进取、优质高效、和谐健康”的企业精神,不断寻求创新与突破,逐步使公司成为现代化、高科技制药企业。

莎普爱思的未来将坚持以市场为导向,发展为主题,科技创新为核心。以保护和增进人民健康、提高人民福祉为目标。我们确信莎普爱思的无限“关爱”会遍及中国,走向世界。

Since its establishment in 1978, the company has gone through the transformation from "state-owned Zhejiang Pinghu pharmaceutical factory" to "Zhejiang Pinghu pharmaceutical factory (joint stock cooperation)" to "Zhejiang Pinghu sapais Pharmaceutical Co., Ltd." and then to "Zhejiang sapais Pharmaceutical Co., Ltd." and finally changed its name to "Zhejiang sapais pharmaceutical Co., Ltd." on December 15, 2008, with the current registered capital of 49 million yuan RMB. As a comprehensive pharmaceutical enterprise specializing in drug R & D, production and operation, the company has been listed as "national high-tech enterprise", "one hundred enterprises with the most investment value in Zhejiang Province", "one thousand growth star enterprises in Zhejiang Province", "Zhejiang provincial enterprise technology center", "provincial high-tech research and development center", "Zhejiang standard innovation enterprise" "Jiaxing key enterprise technology innovation team", "academician expert workstation" and other honorary titles. At present, the company has 10 dosage forms of large capacity injection (glass bottles, plastic bottles and multi-layer coextrusion film bags), oral solution, eye drops, tablets (including cephalosporins), hard capsules (including cephalosporins), suppositories, granules (including cephalosporins), dry suspension (including cephalosporins), washing agents, and approval numbers of nearly 100 specifications of products. The new anti cataract drug "sapais" eye drops and the new anti glaucoma drug "Daliang" eye drops are listed in the "National Torch Program project". "Saps eye drops" also won the titles of national key scientific and technological research projects, national key new products, Zhejiang famous brand products, etc., and is the first national class II ophthalmic specialty new drug in China. In the past few decades, with its high quality products and good reputation, the company has won the market and sold its products to all parts of the country under the increasingly fierce market competition, and achieved good economic benefits. In recent years, the sales volume and sales volume of the company have been increasing year by year. It is a listed company supported by Pinghu City. In the highly competitive pharmaceutical market, our company always adheres to the development of science and technology, strengthening management, ensuring quality, and constantly launches various new products independently researched and developed. The company adheres to the enterprise spirit of "scientific and technological innovation, truth-seeking and enterprising, high-quality and efficient, harmonious and healthy", constantly seeks innovation and breakthrough, and gradually makes the company become a modern, high-tech pharmaceutical enterprise. In the future, SAPS will adhere to the market-oriented, development oriented theme and technological innovation as the core. With the goal of protecting and promoting people's health and improving people's well-being. We are sure that the infinite "love" of sapeus will spread all over China and go to the world.

本文链接: https://brand.waitui.com/a5a71ec58.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

MiniMax考虑赴港IPO?知情人士:属实,仍处于初步筹备阶段

AI独角兽稀宇科技(MiniMax)正考虑在香港进行首次公开募股(IPO)。6月18日,接近MiniMax的知情人士表示,MiniMax内部确实有类似想法,但目前仍处于初步筹备阶段。MiniMax成立于2021年,2024年3月,MiniMax获6亿美元A轮融资,投后估值25亿美元,由阿里巴巴领投,此前融资的投资方也包括腾讯等。据媒体报道称,MiniMax的实际估值目前已经超过2024年所报道过的“25亿美元”。(澎湃)

29分钟前

美国上周首次申领失业救济人数24.5万

美国劳工部6月18日公布数据显示,美国上周首次申领失业救济人数24.5万。(界面)

29分钟前

美股大型科技股盘前多数上涨,奈飞涨0.6%

36氪获悉,美股大型科技股盘前多数上涨,截至发稿,奈飞涨0.6%,特斯拉涨0.37%,英伟达涨0.29%,Meta涨0.26%,亚马逊涨0.25%,苹果涨0.21%,谷歌涨0.18%;微软跌0.12%。

29分钟前

热门中概股美股盘前多数下跌,阿里巴巴跌超1%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,阿里巴巴、哔哩哔哩、理想汽车跌超1%,京东跌0.76%,拼多多跌0.66%,微博跌0.41%,网易跌0.31%;蔚来涨0.73%,小鹏汽车涨0.35%。

29分钟前

*ST华微:拟筹划股权协议转让事宜,明起停牌

36氪获悉,*ST华微发布公告,公司6月18日收到控股股东上海鹏盛的通知,为推动化解公司面临的资金占用规范类退市风险,其正在依规筹划所持有的公司股份协议转让事宜,该事项后续可能导致公司控制权发生变更。经申请,公司股票将于6月19日(星期四)上午开市起停牌,预计停牌时间不超过2个交易日。

29分钟前

本页详细列出关于莎普爱思的品牌信息,含品牌所属公司介绍,莎普爱思所处行业的品牌地位及优势。
咨询